Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Tuesday, 16'th Sep 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025
04:30pm, Thursday, 28'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Monday, 18'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK)
08:45am, Monday, 18'th Aug 2025
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) on behalf of the company's shareholders. The investigation
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 12'th Aug 2025
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago.
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
07:00am, Thursday, 07'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
04:30pm, Wednesday, 06'th Aug 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 30'th Jul 2025
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 16'th Jul 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 17'th Jun 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
